Further, for EGFR-mutated NSCLC with MET amplification treatment, efficacy of combination of MET–TKIs with EGFR–TKIs has been preliminarily approved by several clinical trials [29,30]. This evidence concerns the gene MET and non-small cell lung carcinoma.